Endo adds Sumavel DosePro to specialty Rx portfolio

DUBLIN — Endo International announced that its affiliates have acquired rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use from Zogenix. The product is a needle-free delivery system for sumatriptan. Sumavel DosePro is used to treat adults who have been diagnosed with acute migraine or cluster headaches.



"We are pleased to acquire the worldwide rights to Sumavel DosePro to enhance our branded pharmaceutical portfolio," said Rajiv De Silva, president and CEO of Endo. "We are focused on completing a seamless transition of commercial support for this currently marketed product that will leverage our existing commercial expertise in pain and migraine management and the current infrastructure of our branded pharmaceuticals business overall."



Under the terms of the agreement, Endo is acquiring the product for an upfront payment of $85 million, as well as rights to additional cash payments based on certain commercial milestones. Additionally, the company will take on an existing third-party royalty obligation on net sales.